Catabasis Pharmaceuticals Inc buy PlusUltra
Start price
02.12.20
/
50%
€11.72
Target price
02.12.21
-
Performance (%)
-39.70%
End price
03.12.21
-
Summary
This prediction is currently being closed. The BUY prediction by PlusUltra for Catabasis Pharmaceuticals Inc is performing very badly with a performance of -39.70%. PlusUltra has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Catabasis Pharmaceuticals Inc | - | - | - | - |
| iShares Core DAX® | 4.015% | 2.971% | 16.492% | 19.144% |
| iShares Nasdaq 100 | 2.755% | 0.503% | 40.029% | 50.636% |
| iShares Nikkei 225® | -0.826% | -5.057% | 14.566% | 2.379% |
| iShares S&P 500 | 2.330% | 0.720% | 30.194% | 44.181% |
According to PlusUltra what are the pros and cons of Catabasis Pharmaceuticals Inc for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by PlusUltra for this prediction
In the thread Catabasis Pharmaceuticals Inc diskutieren
Buy Catabasis Pharmaceuticals Inc
In the thread Trading Catabasis Pharmaceuticals Inc
Die von PlusUltra gewählte maximale Laufzeit wurde überschritten